Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Deconvoluting the Obesity and Breast Cancer Link: Secretome, Soil and Seed Interactions

Abstract

Obesity is associated with increased risk of breast cancer in postmenopausal women and is linked with poor prognosis in pre- and postmenopausal breast cancer patients. The mechanisms underlying the obesity-breast cancer connection are becoming increasingly clear and provide multiple opportunities for primary to tertiary prevention. Several obesity-related host factors can influence breast tumor initiation, progression and/or response to therapy, and these have been implicated as key contributors to the complex effects of obesity on cancer incidence and outcomes. These host factors include components of the secretome, including insulin, insulin-like growth factor-1, leptin, adiponectin, steroid hormones, cytokines, vascular regulators, and inflammation-related molecules, as well as the cellular and structural components of the tumor microenvironment. These secreted and structural host factors are extrinsic to, and interact with, the intrinsic molecular characteristics of breast cancer cells (including breast cancer stem cells), and each will be considered in the context of energy balance and as potential targets for cancer prevention.

This is a preview of subscription content, log in to check access.

Fig. 1

Abbreviations

mTOR:

mammalian target of rapamycin

IGF-1:

Insulin-like growth factor-1

ER:

estrogen receptor

miRs:

microRNAs

References

  1. 1.

    Finucane MM et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557–67.

  2. 2.

    Flegal KM et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307(5):491–7.

  3. 3.

    Prevention, C.f.D.C.a. 2012; Available from: http://www.cdc.gov/nchs/fastats/bodymeas.htm.

  4. 4.

    Available from: http://www.iaso.org/resources/obesity-data-portal/resources/charts/.

  5. 5.

    Reeves GK et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134.

  6. 6.

    Yang XR et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250–63.

  7. 7.

    Prat A et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res: BCR. 2010;12(5):R68.

  8. 8.

    Dogan S et al. Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-alpha mice. Breast Cancer Res. 2007;9(6):R91.

  9. 9.

    Dunlap SM et al. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev Res. 2012;5(7):930–42.

  10. 10.

    Giles ED et al. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res. 2012;72(24):6490–501.

  11. 11.

    Hakkak R et al. Obesity increases the incidence of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in an ovariectomized Zucker rat model. Int J Oncol. 2007;30(3):557–63.

  12. 12.

    Cleary MP et al. Diet-induced obesity and mammary tumor development in MMTV-neu female mice. Nutr Cancer. 2004;50(2):174–80.

  13. 13.

    Ford NA et al. IGF1 dependence of dietary energy balance effects on murine Met1 mammary tumor progression, epithelial-to-mesenchymal transition, and chemokine expression. Endocr-Relat Cancer. 2013;20(1):39–51.

  14. 14.

    Mizuno NK et al. Combination of intermittent calorie restriction and eicosapentaenoic acid for inhibition of mammary tumors. Cancer Prev Res. 2013;6(6):540–7.

  15. 15.

    Hursting SD, Hursting MJ. Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol. 2012;32(8):1766–70.

  16. 16.

    Makridakis M, Vlahou A. Secretome proteomics for discovery of cancer biomarkers. J Proteome. 2010;73(12):2291–305.

  17. 17.

    Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571–3.

  18. 18.

    Brown KJ et al., The human secretome atlas initiative: Implications in health and disease conditions. Biochimica et Biophysica Acta, 2013.

  19. 19.

    Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011;13(6):227.

  20. 20.

    Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 2010;1212:E1–19.

  21. 21.

    Karastergiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol. 2010;318(1–2):69–78.

  22. 22.

    Nam SY et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord. 1997;21(5):355–9.

  23. 23.

    Hursting SD et al., Calories and cancer: the role of insulin-like growth factor-1, in The IGF system and cancer, D. Leroith, Editor 2011, Springer, NY. p. 231–243.

  24. 24.

    Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915–28.

  25. 25.

    Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010;20(1):87–90.

  26. 26.

    Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009;21(5):656–64.

  27. 27.

    Moore T et al. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev Res (Phila). 2008;1(1):65–76.

  28. 28.

    De Angel RE et al. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Mol Carcinog. 2013;52(6):446–58.

  29. 29.

    Nogueira LM et al. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocr Relat Cancer. 2012;19(1):57–68.

  30. 30.

    Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest. 2011;121(6):2087–93.

  31. 31.

    Gross A et al., Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev, 2013.

  32. 32.

    Wu MH et al. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009;100(4):578–82.

  33. 33.

    Mantzoros CS et al. Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer. 1999;80(4):523–6.

  34. 34.

    Petridou E et al. Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control. 2000;11(5):383–8.

  35. 35.

    Stattin P et al. Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat. 2004;86(3):191–6.

  36. 36.

    Harris HR et al. Plasma leptin levels and risk of breast cancer in premenopausal women. Cancer Prev Res (Phila). 2011;4(9):1449–56.

  37. 37.

    Cirillo D et al. Leptin signaling in breast cancer: an overview. J Cell Biochem. 2008;105(4):956–64.

  38. 38.

    Vaiopoulos AG et al. The role of adiponectin in human vascular physiology. Int J Cardiol. 2012;155(2):188–93.

  39. 39.

    Miyoshi Y et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9(15):5699–704.

  40. 40.

    Mantzoros C et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89(3):1102–7.

  41. 41.

    Tian YF et al. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer. 2007;14(3):669–77.

  42. 42.

    Tworoger SS et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007;92(4):1510–6.

  43. 43.

    Barb D et al. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007;86(3):s858–66.

  44. 44.

    Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul. 2009;43(4):157–68.

  45. 45.

    Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008;114(1):71–83.

  46. 46.

    Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441(7092):431–6.

  47. 47.

    Del Prete A et al. Molecular pathways in cancer-related inflammation. Biochem Med (Zagreb). 2011;21(3):264–75.

  48. 48.

    Chen DC et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2006;237(1):109–14.

  49. 49.

    Ashizawa N et al. Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecol Oncol. 2010;119(1):65–9.

  50. 50.

    Cleary MP et al. Targeting the adiponectin: leptin ratio for postmenopausal breast cancer prevention. Front Biosci (Schol Ed). 2009;1:329–57.

  51. 51.

    Key TJ et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218–26.

  52. 52.

    Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354(3):270–82.

  53. 53.

    Pequeux C et al. Stromal estrogen receptor-alpha promotes tumor growth by normalizing an increased angiogenesis. Cancer Res. 2012;72(12):3010–9.

  54. 54.

    Brodie AM, Marsh D, Brodie HJ. Aromatase inhibitors–IV. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dione. J Steroid Biochem. 1979;10(4):423–9.

  55. 55.

    Basu S et al. Eicosanoids and adipokines in breast cancer: from molecular mechanisms to clinical considerations. Antioxid Redox Signal. 2013;18(3):323–60.

  56. 56.

    Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci. 2011;1229:45–52.

  57. 57.

    Subbaramaiah K et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila). 2011;4(3):329–46.

  58. 58.

    Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–46.

  59. 59.

    Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 2008;99(8):1501–6.

  60. 60.

    Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol. 2009;9(4):351–69.

  61. 61.

    Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res. 2008;659(1–2):15–30.

  62. 62.

    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.

  63. 63.

    Charriere G et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem. 2003;278(11):9850–5.

  64. 64.

    Allavena P et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1–9.

  65. 65.

    Calabro P, Yeh ET. Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. Subcell Biochem. 2007;42:63–91.

  66. 66.

    Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540–50.

  67. 67.

    Kulbe H et al. The chemokine network in cancer–much more than directing cell movement. Int J Dev Biol. 2004;48(5–6):489–96.

  68. 68.

    Allavena P et al. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 2008;222:155–61.

  69. 69.

    Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007;117(9):2362–8.

  70. 70.

    Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9(4):777–94.

  71. 71.

    Liu Y et al. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses’ Health Study. Breast Cancer Res Treat. 2011;129(1):175–84.

  72. 72.

    Chen CT et al. Targeting the IKKbeta/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Mol Cancer Ther. 2012;11(10):2212–21.

  73. 73.

    Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol. 2012;157(3):291–8.

  74. 74.

    Carter JC, Church FC. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-gamma and plasminogen activator inhibitor-1. PPAR Res. 2009;2009:345320.

  75. 75.

    Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord. 2004;28(11):1357–64.

  76. 76.

    Muldowney 3rd JA et al. Pentoxifylline lowers plasminogen activator inhibitor 1 levels in obese individuals: a pilot study. Angiology. 2012;63(6):429–34.

  77. 77.

    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

  78. 78.

    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.

  79. 79.

    Hollstein M et al. p53 mutations in human cancers. Science. 1991;253(5015):49–53.

  80. 80.

    Molchadsky A et al. p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death Differ. 2013;20(5):774–83.

  81. 81.

    Park H et al. A high-fat diet increases angiogenesis, solid tumor growth, and lung metastasis of CT26 colon cancer cells in obesity-resistant BALB/c mice. Mol Carcinog. 2012;51(11):869–80.

  82. 82.

    Dhasarathy A, Kajita M, Wade PA. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol. 2007;21(12):2907–18.

  83. 83.

    Liu G, Schwartz JA, Brooks SC. Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res. 2000;60(7):1810–4.

  84. 84.

    Hurd C et al. Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells. Oncogene. 1999;18(4):1067–72.

  85. 85.

    Konduri SD et al. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci U S A. 2010;107(34):15081–6.

  86. 86.

    Shirley SH et al. Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res. 2009;69(8):3405–14.

  87. 87.

    Zhang X et al. Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene. 2005;24(26):4220–31.

  88. 88.

    Fuchs-Young R et al. P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res Treat. 2011;130(2):399–408.

  89. 89.

    Freeman EW et al. Obesity and reproductive hormone levels in the transition to menopause. Menopause. 2010;17(4):718–26.

  90. 90.

    Wolff AC et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18–43.

  91. 91.

    Skliris GP et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol. 2003;201(2):213–20.

  92. 92.

    Luo J et al. A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J. 2010;10(4):278–91.

  93. 93.

    Wang ZV et al. Identification and characterization of a promoter cassette conferring adipocyte-specific gene expression. Endocrinology. 2010;151(6):2933–9.

  94. 94.

    Karastergiou K et al. Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells. Arterioscler Thromb Vasc Biol. 2010;30(7):1340–6.

  95. 95.

    Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature. 2009;458(7239):725–31.

  96. 96.

    Elkabets M et al. mTORC1 inhibition is required for sensitivity to PI3K p110alpha Inhibitors in PIK3CA-mutant breast cancer. Sci Trans Med. 2013;5(196):196ra99.

  97. 97.

    Njiaju UO, Olopade OI. Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. Breast J. 2012;18(5):436–42.

  98. 98.

    Ford NA et al. Obesity, independent of p53 gene dosage, promotes mammary tumor progression and upregulates the p53 regulator MicroRNA-504. PLoS One. 2013;8(6):e68089.

  99. 99.

    Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009;15(9):1010–2.

  100. 100.

    Velasco-Velazquez MA et al. Breast cancer stem cells. Int J Biochem Cell Biol. 2012;44(4):573–7.

  101. 101.

    Zheng Q et al. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr Relat Cancer. 2011;18(4):491–503.

Download references

Acknowledgments

SDH is funded, in part, by grants from the National Cancer Institute (R01CA129409 and R01CA135306), the Breast Cancer Research Foundation (UTA09-001068), and the National Institute of Environmental Health Sciences (P30ES007784). NAF was supported by an American Institute for Cancer Research Postdoctoral Fellowship and KLD was supported by a predoctoral fellowship from the National Institute of Environmental Health Sciences (T32ES07247).

Author information

Correspondence to Stephen D. Hursting.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ford, N.A., Devlin, K.L., Lashinger, L.M. et al. Deconvoluting the Obesity and Breast Cancer Link: Secretome, Soil and Seed Interactions. J Mammary Gland Biol Neoplasia 18, 267–275 (2013). https://doi.org/10.1007/s10911-013-9301-9

Download citation

Keywords

  • Obesity
  • Breast cancer
  • Leptin
  • Insulin
  • Inflammation
  • p53